Panulisib
Panulisib (P7170; AK151761) is an orally active inhibitor of PI3K (IC50 = 2.2 nM) and mTOR (IC50 = 4.4 nM). Panulisib inhibits ALK1 and DNA-PK, two enzymes that respectively participate in angiogenesis and DNA repair, with IC50 values of 47 nM and 1.5 nM respectively. Panulisib inhibits cell proliferation and apoptosis. Panulisib can be used for research on breast cancer and non-small cell lung cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1356033-60-7
- 分子式: C27H20F3N9
- 分子量:527.50
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1356033-60-7
-
分子量 527.50
-
分子式 C27H20F3N9
-
SMILES
N#C/N=C(N1C2=CC=C(C(C)(C#N)C)N=C2)\N(C)C3=C1C4=CC(C5=CC(C(F)(F)F)=C(N)N=C5)=CC=C4N=C3
-
別名
P7170; AK151761
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Jalota-Badhwar A, et al. P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity. Mol Cancer Ther. 2015 May;14(5):1095-106. [Content Brief]
[2]. Bean JR, et al. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat. 2015 Jan;149(1):69-79. [Content Brief]
[3]. Venkatesha VA, et al. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer. Mol Cancer. 2014 Dec 2;13:259. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
- Panulisib
- 1356033-60-7
- P7170
- AK151761
- P 7170
- P-7170
- AK151761
- AK 151761
- AK-151761
- PI3K
- mTOR
- Anaplastic lymphoma kinase (ALK)
- DNA-PK
- Apoptosis
- mTOR inhibitor
- ALK1 inhibitor
- PI3K/mTOR pathway
- anticancer therapy
- angiogenesis inhibition
- kinase inhibitor
- targeted therapy
- xenograft models
- clinical development
- Inhibitor
- inhibitor
- inhibit